^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NX-019

    i
    Other names: NX-019
    Associations

    News

    Trials
    Company:
    Nalo Therap
    Drug class:
    Associations

    News

    Trials
    11ms
    A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (clinicaltrials.gov)
    P1, N=258, Active, not recruiting, Nalo Therapeutics Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Dec 2025 | Trial primary completion date: Feb 2027 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q
    |
    NX-019
    almost2years
    A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (clinicaltrials.gov)
    P1, N=258, Recruiting, Nalo Therapeutics Inc. | N=178 --> 258
    Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q
    |
    NX-019
    over3years
    A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (clinicaltrials.gov)
    P1, N=178, Recruiting, Nalo Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q
    |
    NX-019
    over3years
    A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (clinicaltrials.gov)
    P1, N=178, Not yet recruiting, Nalo Therapeutics Inc.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q
    |
    NX-019